ZURA BIO LIMITED Net Income (Loss) Attributable to Redeemable Noncontrolling Interest
ZURA BIO LIMITED (ZURA) reported Net Income (Loss) Attributable to Redeemable Noncontrolling Interest of -$203.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest · last filed 2025-03-25
- ZURA BIO LIMITED net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-12-31 was $0.00.
- ZURA BIO LIMITED net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-09-30 was $0.00.
- ZURA BIO LIMITED net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-06-30 was $0.00.
- ZURA BIO LIMITED net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2023-03-31 was -$203.00K.
- ZURA BIO LIMITED net income (loss) attributable to redeemable noncontrolling interest for fiscal 2023 was -$203.00K.
| Period end | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 11 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | -$203.00K 10-K · filed 2025-03-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$203.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$203.00K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$203.00K 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | -$1.59M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |